Glimisave Nexa 1mg/1000mg Tablet is a combination oral antidiabetic medication containing Glimepiride (1mg) and Metformin (1000mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. This dual mechanism provides effective glycemic control in patients inadequately managed by diet and exercise alone. Glimisave Nexa is typically prescribed when monotherapy with either agent is insufficient or when combination therapy is deemed appropriate by the healthcare provider. The tablet should be taken orally with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, diarrhea, and abdominal discomfort. Patients should be monitored regularly for blood glucose levels, renal function, and potential adverse effects including hypoglycemia, particularly due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or during periods of acute illness. Glimisave Nexa should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision to optimize therapeutic outcomes and reduce the risk of diabetes-related complications.